Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799433 | 0.78 | ADORA2B (0.45) | ERCC5FEN1ALDH1A1ADORA2B | |
| SCHEMBL13834710 | 0.75 | ERCC5 (0.33) | ERCC5FEN1TRPA1KDM4EALDH1A1 | |
| SCHEMBL9972877 | 0.72 | KMT2A (0.33) | ERCC5FEN1TRPA1KDM4EALDH1A1 | |
| SCHEMBL9972886 | 0.69 | KDM4E (0.31) | KDM4EALDH1A1 | |
| SCHEMBL13834835 | 0.69 | TRPA1 (0.38) | TRPA1ALDH1A1ADORA2B | |
| SCHEMBL9972891 | 0.68 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL13835019 | 0.68 | TRPA1 (0.37) | TRPA1KDM4EALDH1A1ADORA2B | |
| SCHEMBL13834829 | 0.68 | TRPA1 (0.46) | ERCC5FEN1TRPA1ALDH1A1ADORA2B | |
| SCHEMBL13175034 | 0.67 | TRPA1 (0.45) | ERCC5FEN1TRPA1KDM4EALDH1A1 | |
| SCHEMBL12611139 | 0.66 | ADRA2C (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | TRPA1, TRPV1, TRPV2 | ERCC5 3319/4885FEN1 4573/4885TRPA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.